For Europe ☐ several Swiss shares are listed on the sales list of a US bank

Novartis: Redburn lowers to neutral (buy) to 105 (116) Fr. Harvest time in the gene therapy business can wait longer than expected.

SIG Combibloc: Barclays goes to equal weight until 21.50 (22) Fr. Warns against rising security costs for aluminium and polymers.

Barry Callebaut: share for Goldman Sachs a purchase up to 2700 (2650) Fr.

Dätwyler: Stifel is for buy up to 430 (385) Fr. A step forward in the Chinese health market is an important and pleasing step.

Lindt&Sprüngli: Goldman Sachs will es wissen, erhöht auf 130'000 (117'000) Fr. mit BUY. Sieht den Premiumschokoladehersteller gut gegen steigende Rohstoffpreise gewappnet.

Lonza: Benlysta from Great Britain Glaxo beckons an extended application approval in the UK. Lonza is entrusted with the production of this antibody.

Nestlé: Goldman Sachs is for buy up to 140 (130) Fr. The adjustments take account of recent inflation trends and currency shifts.

Orascom: Samih Sawiris handed over the VR Bureau to the next General Assembly. Son Naguib takes over. ZKB remains for MARKTGEWICHTEN, Kepler Cheuvreux for hold up to 9.50 Fr.

Polyphor: announces first administration of inhalable murepavedin in a patient together with EnBiotix. Important milestone.

Relief Therapeutics: us partner NeuroRx has new compatibility data for Covid-19 active ingredient aviptadil. No new safety concerns have been identified.

Richemont: Oddo increased to 142 (129) Fr. Neutral. Op. profit estimates are increased by an average of 3pc. According to the French investment bank, the French investment bank no longer shares a bargain.

Roche: presents pleasing study results on polivy in lymphoma patients. Ended unsuccessful collaboration with Atea for Covid-19 pill.

Stadler Rail: receives follow-up order for ten more trams from Potsdam. Volume seen at just under €61 million. Credit Suisse nevertheless reduces to 40 (43) Fr. Neutral. Warns of inefficiencies in operation. Kepler Cheuvreux stays for hold until 44 Fr.

UBS: Vontobel sees the largest Swiss bank in the final quarter to increase provisions for the France process by €1.35 billion. Step, however, can be easily combined. Therefore stays for buy until 18.50 Fr.

Vifor: Oddo goes to neutral (outperform) to 167 (146) Fr. CSL & APOs; s Barofferte seems appropriate. Research partners for their part increase to 165 (107) Fr. Hold it.

Strategy: ZKB replaces default values Roche with Novartis and Givaudan by Lonza in its Switzerland portfolio. With the secondary values Bystronic must make room for the new addition Zehnder.

Derivatives: total slump.